IP Library Granted Patent US 10,201,594
Granted Patent B2
US 10,201,594 · App. 15/155,551 · Granted Feb 12, 2019

Compositions and methods for safe treatment of rhinitis

Inventors: Curtis L. Ruegg (Redwood City, CA); Hongran Fan Stone (Beijing, CN); Jacob M. Waugh (Palo Alto, CA)
Assignee: Revance Therapeutics, Inc.
A61K38/4893A61K9/0043A61K38/48A61K47/10A61K47/34A61K47/42A61M31/00C12Y304/24069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,201,594
App. No.
15/155,551
Granted
Feb 12, 2019
Kind
B2
Abstract

Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis.

Claims (12)

1. A method for treating rhinitis, the method comprising

intranasally administering a therapeutically effective amount of a botulinum toxin composition to a patient in need of treatment; wherein said botulinum toxin composition comprises a purified 150 kDa botulinum neurotoxin isolated from botulinum toxin type A;

a carrier molecule comprising a polypeptide having the amino acid sequence RKKRRQRRR-Q-(K) 15 -Q-RKKRRQRRR (SEQ ID NO: 18); and

a viscosity modifier in the form of a gel or a solution that forms a gel upon an increase in temperature;

wherein said intranasal administration provides a dose of the purified botulinum neurotoxin of 250 U to 12,500 U to said patient.

2. The method according to claim 1 wherein said intranasal administration provides a dose of the purified botulinum neurotoxin of about 1,250 U to said patient.

3. The method according to claim 1 , wherein the concentration of said botulinum toxin composition is 6,250 U/mL.

4. The method according to claim 1 , wherein the viscosity modifier agent is poloxamer 407.

5. The method according to claim 1 , wherein said composition is applied using a single intranasal application for a duration of 5 seconds to 60 minutes.

6. The method according to claim 1 , wherein said composition is applied using a single intranasal application for a duration of 30 seconds to 45 minutes.

7. The method according to claim 1 , wherein said composition is applied using a single intranasal application for a duration of 1 minute to 30 minutes.

8. The method according to claim 1 , wherein said composition is applied using a single intranasal application for a duration of 30 minutes.

Assignments (6)
SECURITY INTEREST Recorded Feb 17, 2025
From: REVANCE THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 070239/0739 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2025
From: ATHYRIUM BUFFALO LP
To: REVANCE THERAPEUTICS, INC
Reel/Frame 070153/0630 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0663 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; BELLUS MEDICAL, LLC; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2022
From: RUEGG, CURTIS L.; FAN STONE, HONGRAN; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 059303/0725 →
SECURITY INTEREST Recorded Mar 18, 2022
From: REVANCE THERAPEUTICS, INC.
To: ATHYRIUM BUFFALO LP
Reel/Frame 059437/0654 →
Continuity (3)
Continuation 14065379 · Oct 28, 2013
Provisional Application 61719462 · Oct 28, 2012
Related Publication 20160250302A1 · Sep 1, 2016
Cited By (2)
US 12,409,211 US 12,653,804